You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Molika Ashford covers personalized medicine and molecular diagnostics for GenomeWeb.
Backed by large public companies and growing prospective data, the first molecular blood tests to screen for multiple cancers are approaching commercialization.
Early data around an initial composite assay showed it can predict immunooncology drug responses more accurately than tumor mutational burden.
The company hopes the data will help convince clinicians to adopt the algorithm in CRC as it pushes forward validations for other areas like pancreatic and ovarian tumors.
The company believes its tests can already help oncologists better assess post-surgery risk, though prospective validation would be necessary for broad claims.
Increased incidental detection of clonal hematopoiesis and new considerations for mutations in myelodysplastic precursors herald improved precision medicine strategies.
As adoption of personalized medicines has accelerated over the last four years, so has the number of marketed genetic and exome tests.
Though Guardant and Foundation have pioneered a path through the FDA for liquid biopsy tests, label differences highlight complex choices for oncologists.
Researchers showed that ctDNA levels predicted who would respond to first-line immune checkpoint inhibition but were not useful in second-line therapy.
Researchers showed benefit from chemotherapy in patients classified as high risk by the test, independent of their EGFR mutation status.
Researchers are continuing to collect data on economic, racial, and other factors that could be addressed to make precision medicine access more equitable.